If the readout of the 3rd cohort shows promise of disease control or better. we may have the 1st CarT drug that can tackle solid tumour cancer.
That may be the catalyst you are looking for. Remember that the NK trial underway now is of no cost to CHM.
Luckily CHM is run by a group of highly experienced folk. This is not their first rodeo.With the tiny SOI now, and incredibly low market cap for its pipeline. even with dilution now, thd potential of many multiples of upside is still available.
If the readout of the 3rd cohort shows promise of disease...
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.001(12.5%) |
Mkt cap ! $9.068M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.5¢ | $2.418K | 526.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 11217085 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 15687025 | 18 |
View Market Depth
| Last trade - 15.52pm 01/07/2025 (20 minute delay) ? |
| CHM (ASX) Chart |